Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-12
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026RLMD — Relmada Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
$7.14+70.41%Market cap698.57M
- Latest Close
- $7.14
- 30-Day Move
- +70.4%
- Market Cap
- $699M
- Shares Outstanding
- 73,330,000
- P/B Ratio
- 4.09
- ROE
- -66.3%
Analyst consensus: Buy · 11 analysts
NASDAQ:RLMDPharmaceuticals / PharmaceuticalsDelayed public snapshot
Relmada Therapeutics Inc
A read-only Alphactor snapshot forRelmada Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$7.14
30-Day Move
+70.4%
Market Cap
$699M
Shares Outstanding
73,330,000
P/B Ratio
4.09
ROE
-66.3%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$7.14
+70.4%last 90 delayed daily bars
Market cap$699M
90D High
$7.94
90D Low
$3.22
Avg Volume
1,437,822
What stands out
Gross margin is running at 0.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -500.0%, useful for comparing RLMD against peers in Pharmaceuticals.
RLMD is up 70.4% over the last 30 trading days shown on this page.
Latest operating income is $-20M, which helps anchor the headline ratios with an actual earnings figure.
Fundamentals snapshot
Latest Close
$7.14
30-Day Move
+70.4%
Market Cap
$699M
Shares Outstanding
73,330,000
P/B Ratio
4.09
ROE
-66.3%
ROA
-61.1%
Gross Margin
0.0%
Operating Margin
-500.0%
Net Margin
-500.0%
Debt / Equity
0
Current Ratio
14.62
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-20M
Net Income
$-20M
Gross Margin
0.0%
Net Margin
-50000.0%
Current Ratio
14.62
Debt / Equity
0.00
Quality snapshot
Altman Z
44.59
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.80x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-161M | $-157M | $-104M |
| 2023-12-31 | $0 | $-104M | $-99M | $-52M |
| 2024-12-31 | $0 | $-84M | $-80M | $-52M |
| 2025-12-31 | $0 | $-59M | $-57M | $-46M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-02-26
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-07-31
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-04-28
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-04-27
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$3M
Sell Value
$0
Buys
17
Sells
0
Buy Value
$3M
Sell Value
$0
Buy/Sell Ratio
17.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-15 | TRAVERSA SERGIO | Buy | 27,500 | $4.12 |
| 2025-12-15 | Shenouda Maged | Buy | 11,665 | $4.12 |
| 2025-12-12 | CASAMENTO CHARLES J | A | 164,000 | $0.00 |
| 2025-12-12 | TRAVERSA SERGIO | A | 1,198,000 | $0.00 |
| 2025-12-12 | Shenouda Maged | A | 828,000 | $0.00 |
| 2025-12-12 | Ence Chuck | A | 828,000 | $0.00 |
| 2025-12-12 | Fedeli Fabiana | A | 164,000 | $0.00 |
| 2025-12-12 | GLASSPOOL JOHN | A | 164,000 | $0.00 |
Institutional holders snapshot
Marshall Wace
Filed 2026-02-13
$15M
--
BlackRock
Filed 2024-05-10
$3M
--
Renaissance Technologies
Filed 2026-02-12
$893,550
+9.0%
Citadel Advisors
Filed 2026-02-17
$169,533
--
Analyst consensus?
Rating(?)
4.27
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
11
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.